





Company Identity


- Privately owned pharmaceutical company
- Established: 1970
- Company employees: 406
- Production facilities: Located in Athens covering 14.000 m2
- Headquarters: Athens, Greece



Business sectors

- Domestic sales of own and in-licensed products
- Development and licensing-out of generic & generic plus products
- Production of own products and contract manufacturing








Human resources

- Although Rafarm is a company of state-of-the-art technologies, we value highly the well-being of our people
- We attract and develop top talent employees and we strive to provide them with all the means for a balanced and full professional and personal life





Representation in Greece

Sandoz	Austria	SANDOZ A Novartis Division
SSI Statens Serum Institut	Denmark	STATENS SERUM INSTITUT
SBL	Sweden	• Crucell servaccines.
Health Watch Swiss	Switzerland	h ealthwatchswiss
SMB	Belgium	
Rosemont Pharmaceuticals	UK	Rosemont The source of liquid solutions.
Lallemand Pharma Int.	France	LALLEMAND
Medice	Germany	MEDICE
Apotex	Canada	











US Market

- Rafarm is developing a number of sterile injectable and ophthalmic dossiers to be submitted to FDA in order to trigger the agency's inpection and get approval
- First two products already filled in June 2015
- -New developments for US market 3-4/year



Manufacturing-own and third party

- 20% CAGR the last 5 years
- -Manufacturing for more than 50 companies in EU
- Expertise on sterile ophthalmic and injectable products





Production facilities





Production facilities

- Covering 14.000 m²
- Pharmaceutical forms produced
 - Solids Liquid-semi solid Creams Sterile products





Production facilities

- Anual capacity (one shift)
 - 400.000.000 tablets
 - 10.000.000 vials

10.000.000 ampoules 10.000.000 ophthalmic solutions





Quality control

- EU GMP approved
- TGA approved
- The company is implementing a large investment program in production facilities and quality control and is preparing for the FDA inspection during 2017





Research & Development Operations

- Current Surface Area
- Total employees
- Educational status
- Functions

600 m² 38 10 BScs, 17 MScs, 11 Ph.D Finished Product Formulation Development Finished Product Analytical Development Active Pharmaceutical Ingredients Evaluation Clinical Studies Monitoring Intellectual Property Investigation Tech Transfer Activities



Research & Development Operations

- Pharmaceutical Forms
- Technology Capabilities

— Focus

Sterile products (Ophthalmics and Injectables), Oral solids, Semi solids, Oral Solutions, Nasal sprays Solutions, Suspensions, Multiparticulates, IR Tablets, Delayed Release Systems, ODTs, Chewable Tablets, HG Capsules, Ointments, Creams Ophthalmics and Injectables





New sterile area

- Total surface 900 m²
- Investment 15.000.000 \$
- Three independent lines: opthalmic vials | ampoules | vials (up to 15 ml)
- Yearly production capacity (one shift): 10 mil ophalmic vials | 10 mil ampoules | 10 mil vials





Enviroment

- Enviroment protection is a main concern at Rafarm
- We are very strict in applying the regulations relative to the use of water and gas emissions.
 - All of our activities are conducted with the greatest respect for the environment





Strategy for growth

- Focusing on selected production areas with high technological content (sterile products)
- Strengthening our presence in the local market through expansion of our product portfolio and partnerships with strong international players. Readiness to invest on special projects for the Greek market
- Expanding presence in foreign market by means of wider geographical coverage and wider product portfolio
- Focus on US generics market with products characterized by high entry barriers and challenging IP



Excellence in generics



Thank you for your attention